Katoh, Norito
Ikeda, Masanori
Ohya, Yukihiro
Murota, Hiroyuki
Hu, Xiaofei
Liu, John
Niiyama, Hayato
Sasaki, Takuya
Raymundo, Eliza M.
Saeki, Hidehisa
Clinical trials referenced in this document:
Documents that mention this clinical trial
Acne Among Japanese Patients with Atopic Dermatitis Receiving Upadacitinib in the Phase 3 Rising Up Study
https://doi.org/10.1007/s13555-023-00961-9
Safety and Efficacy of Upadacitinib for Atopic Dermatitis in Japan: 2-Year Interim Results from the Phase 3 Rising Up Study
https://doi.org/10.1007/s13555-022-00842-7
Safety and Efficacy of Upadacitinib for Atopic Dermatitis in Japan: Analysis of the 3-Year Phase 3 Rising Up Study
https://doi.org/10.1007/s13555-023-01071-2
Article History
Received: 19 September 2023
Accepted: 9 November 2023
First Online: 21 December 2023
Declarations
:
: N. Katoh has received honoraria as a speaker/consultant for AbbVie, Celgene Japan, Eli Lilly Japan, Janssen Pharma, Kyowa Kirin, LEO Pharma, Maruho, Pfizer, Sanofi, and Taiho Pharmaceutical. He has received grants as an investigator from AbbVie, A2 Healthcare, Boehringer Ingelheim Japan, Janssen Pharma, Kyowa Kirin, LEO Pharma, Maruho, Mitsubishi Tanabe, Sun Pharma, and Torii Pharmaceutical. M. Ikeda has received a scholarship donation from the Central Research Institute of Pias. He has participated in clinical studies and/or has received honoraria as a speaker/consultant for AbbVie, AstraZeneca, Eli Lilly, GlaxoSmithKline, Hisamitsu, Maruho, MedImmune, Novo Nordisk, Pfizer, Sanofi, and Yanssen Pharmaceutical. Y. Ohya has received honoraria as a speaker, consultant, and/or for data safety monitoring for AbbVie, Japan Tobacco, Kao, Maruho, Mitsubishi Tanabe Pharma, Nobel Pharma, Otsuka Pharmaceutical, Pfizer, Pierre Fabre, Sanofi/Regeneron, Shino-Test, Sysmex, Torii Pharmaceutical, and Towa Pharmaceutical. He has received grants as an investigator from Fam’s. H. Murota has received funding or grant support from Maruho, Mitsubishi Tanabe Pharma, and SUN Pharma. He has received honorarium as a speaker/consultant from AbbVie, Kaken Pharmaceutical, Lilly, Maruho, Mitsubishi Tanabe Pharma, Otsuka Pharmaceutical, Pfizer, Sanofi, Shiseido Japan, Taiho Pharmaceutical, and Torii Pharmaceutical. X. Hu, H. Niiyama, T. Sasaki, and E.M. Raymundo are current full-time employees of AbbVie Inc., and may hold AbbVie stock and/or stock options. J. Liu is a former (retired) employee of AbbVie Inc., and may hold AbbVie stock and/or stock options. H. Saeki has received honoraria for consultancy from AbbVie, Amgen, Japan Tobacco, LEO Pharma, Lilly Japan, Maruho, Mitsubishi Tanabe Pharma, Novartis, Otsuka Pharmaceutical, Pfizer, Japan, Sanofi, Taiho Pharmaceutical, and Torii Pharmaceutical. He has received funding/grant support from Eisai, Maruho, Taiho Pharmaceutical, Tokiwa Pharmaceutical, and Torii Pharmaceutical.
: All study protocols were reviewed and approved by an institutional review board (Supplementary Table 8). The study was conducted in accordance with the protocol, International Council for Harmonisation guidelines, and applicable regulations, guidelines, and ethical principles originating from the Declaration of Helsinki. All patients provided written informed consent before screening or undergoing study-specific procedures.